


Mali

Region: West Africa

Key information on co-financing

- Gross National Income per capita (2017): \$ 770
- Co-financing status (2019): Initial self-financing
- Country is projected to stay in initial self-financing phase for next 5 years.




Immunisation financing

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
- Government expenditure	\$ 2,717,914	\$ 4,816,882	\$ 4,559,930	\$ 3,180,350	\$ 4,261,159
- Total expenditure	\$ 19,875,721	\$ 19,811,382	\$ 20,357,826	\$ 23,389,350	\$ 26,929,159
- Government as % of total	14%	24%	22%	14%	16%
Routine immunisation					
- Government expenditure	\$ 3,837,632	\$ 5,482,191	\$ 10,381,263	\$ 16,984,040	\$ 7,405,244
- Total expenditure	\$ 26,070,948	\$ 33,078,851	\$ 28,984,352	\$ 40,985,576	\$ 46,356,042
- Government as % of total	15%	17%	36%	41%	16%

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **3%**

Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Yellow Fever	Routine	2002-present	Yes
HepB mono	Routine	2003-2007	No
Pentavalent	Routine	2005-2014	Yes
PCV	Routine	2011-present	Yes
Rota	Routine	2013-present	Yes
HPV	Demonstration	2015-present	No
IPV	Routine	2016 introduction	No
MenA	Routine	2016-present	Yes
MenA	Campaign	2017	No


Co-financing payments

Year	Total amount paid by the country	Co-financed vaccines			
		Vaccine	Year	Amount	Notes
2008	\$ 119,000	-	Yellow Fever	-	-
2009	\$ 181,000	-	Yellow Fever	-	-
2010	\$ 207,000	-	Yellow Fever	-	-
2011	\$ 718,000	-	Yellow Fever	PCV	-
2012	\$ 1,081,000	Penta	Yellow Fever	PCV	-
2013	\$ 595,000	Penta	Yellow Fever	PCV	Rota
2014	\$ 1,028,000	Penta	Yellow Fever	PCV	Rota
2015	\$ 1,072,000	Penta	Yellow Fever	PCV	Rota
2016	\$ 1,678,000	Penta	Yellow Fever	PCV	Rota, MenA
2017	\$ 1,751,000	Penta	Yellow Fever	PCV	Rota, MenA
2018	\$ 1,720,000	Penta	Yellow Fever	PCV	Rota, MenA

Co-financing obligations for 2019

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
Pentavalent	\$ 497,000	698,500
YF	\$ 170,500	139,600
PCV	\$ 525,500	176,000
MenA	\$ 79,500	149,000
Measles	\$ 349,000	1,056,800
Measles follow up ca	\$ 26,000	77,600
Rota	\$ 262,500	114,000
Total	\$ 1,910,000	

Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
MenA Routine	\$ 147,096	\$ 153,258	\$ 158,388	\$ 163,648	\$ 169,016
Penta	\$ 468,181	\$ 488,266	\$ 504,990	\$ 522,143	\$ 539,658
PCV	\$ 390,738	\$ 407,500	\$ 421,458	\$ 435,773	\$ 450,391
Rota	\$ 240,251	\$ 250,557	\$ 259,140	\$ 267,942	\$ 276,930
M routine	\$ 261,442	\$ 369,046	\$ 358,061	\$ 371,082	\$ 576,595
YF routine	\$ 138,370	\$ 144,167	\$ 148,993	\$ 153,940	\$ 158,990
Total	\$ 1,646,077	\$ 1,812,794	\$ 1,851,030	\$ 1,914,528	\$ 2,171,580

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.